title: Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU.
abstract: The objective of this study was to determine the efficacy of systemic colistin therapy in the treatment of nosocomial infections caused by multidrug-resistant Acinetobacter baumannii or Pseudomonas aeruginosa and to study related adverse events. We prospectively studied 78 infections caused by multidrug-resistant A. baumannii or P. aeruginosa that were treated with colistin. The sites of infection were pulmonary infection (78.2%), urinary tract infection (7.7%), primary bloodstream infection (11.5%) and meningitis (2.6%). The mean daily dose of colistin was 5.5+/-1.1 MU/day (range 2-9 MU/day) and the mean duration of colistin therapy was 9.3+/-3.8 days (range 5-21 days). A favourable clinical response to colistin occurred in 60 cases (76.9%). Renal failure occurred in only seven cases. We conclude that colistin can be a safe and effective salvage therapeutic option for nosocomial infections caused by multidrug-resistant A. baumannii or P. aeruginosa.
authors.affiliation: Service de Réanimation Médicale, CHU Habib Bourguiba, route el Ain Km 1, 3029 Sfax, Tunisia. Kallelhat@yahoo.fr
authors.forename: Hatem
authors.initials: H
authors.lastname: Kallel
authors.forename: Mabrouk
authors.initials: M
authors.lastname: Bahloul
authors.forename: Leila
authors.initials: L
authors.lastname: Hergafi
authors.forename: Malek
authors.initials: M
authors.lastname: Akrout
authors.forename: Wajdi
authors.initials: W
authors.lastname: Ketata
authors.forename: Hedi
authors.initials: H
authors.lastname: Chelly
authors.forename: Chokri Ben
authors.initials: CB
authors.lastname: Hamida
authors.forename: Noureddine
authors.initials: N
authors.lastname: Rekik
authors.forename: Adnane
authors.initials: A
authors.lastname: Hammami
authors.forename: Mounir
authors.initials: M
authors.lastname: Bouaziz
mesh_terms: D000151:Acinetobacter Infections / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003091:Colistin / Q000008:administration & dosage / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D007362:Intensive Care Units; D011446:Prospective Studies; D011552:Pseudomonas Infections / Q000188:drug therapy*; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D003091:Colistin